BidaskClub cut shares of Cerus (NASDAQ:CERS) from a hold rating to a sell rating in a research note published on Saturday.

A number of other analysts have also recently issued reports on CERS. Cantor Fitzgerald restated a buy rating and set a $9.00 price objective on shares of Cerus in a research report on Monday, December 10th. Zacks Investment Research cut Cerus from a hold rating to a sell rating in a research report on Monday, January 7th. Finally, ValuEngine upgraded Cerus from a buy rating to a strong-buy rating in a research report on Monday, February 4th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $8.50.

CERS opened at $6.34 on Friday. The company has a market cap of $850.46 million, a PE ratio of -14.41 and a beta of 1.44. The company has a current ratio of 2.79, a quick ratio of 2.53 and a debt-to-equity ratio of 0.26. Cerus has a 1 year low of $4.70 and a 1 year high of $8.05.

Cerus (NASDAQ:CERS) last released its quarterly earnings data on Tuesday, February 26th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). The firm had revenue of $16.50 million for the quarter, compared to the consensus estimate of $18.74 million. Cerus had a negative net margin of 84.15% and a negative return on equity of 65.35%. The business’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.10) earnings per share. As a group, research analysts predict that Cerus will post -0.42 earnings per share for the current year.

In related news, SVP Carol Moore sold 10,886 shares of the business’s stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $6.01, for a total value of $65,424.86. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Kevin Dennis Green sold 23,524 shares of the business’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $2.05, for a total value of $48,224.20. Following the completion of the sale, the chief financial officer now directly owns 66,825 shares in the company, valued at approximately $136,991.25. The disclosure for this sale can be found here. In the last ninety days, insiders sold 57,647 shares of company stock worth $254,880. 6.80% of the stock is owned by insiders.

Hedge funds have recently made changes to their positions in the stock. First Midwest Bank Trust Division boosted its stake in Cerus by 23.4% in the 4th quarter. First Midwest Bank Trust Division now owns 247,343 shares of the biotechnology company’s stock valued at $1,254,000 after buying an additional 46,877 shares in the last quarter. Teachers Advisors LLC boosted its stake in Cerus by 3.2% in the 3rd quarter. Teachers Advisors LLC now owns 312,076 shares of the biotechnology company’s stock valued at $2,250,000 after buying an additional 9,702 shares in the last quarter. Raymond James Trust N.A. acquired a new stake in Cerus in the 4th quarter valued at $71,000. Peregrine Capital Management LLC boosted its stake in Cerus by 28.4% in the 4th quarter. Peregrine Capital Management LLC now owns 2,143,325 shares of the biotechnology company’s stock valued at $10,867,000 after buying an additional 474,106 shares in the last quarter. Finally, Trexquant Investment LP acquired a new stake in Cerus in the 3rd quarter valued at $255,000. 64.51% of the stock is currently owned by institutional investors and hedge funds.

About Cerus

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

See Also: Net Margin – Understanding the Different Kinds of Profit

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.